These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 28889386)

  • 1. Patient-Derived Bladder Cancer Xenografts.
    Bernardo C; Santos LL
    Methods Mol Biol; 2018; 1655():169-175. PubMed ID: 28889386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy.
    Pan CX; Zhang H; Tepper CG; Lin TY; Davis RR; Keck J; Ghosh PM; Gill P; Airhart S; Bult C; Gandara DR; Liu E; de Vere White RW
    PLoS One; 2015; 10(8):e0134346. PubMed ID: 26270481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies.
    Jäger W; Xue H; Hayashi T; Janssen C; Awrey S; Wyatt AW; Anderson S; Moskalev I; Haegert A; Alshalalfa M; Erho N; Davicioni E; Fazli L; Li E; Collins C; Wang Y; Black PC
    Oncotarget; 2015 Aug; 6(25):21522-32. PubMed ID: 26041878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts.
    Wei L; Chintala S; Ciamporcero E; Ramakrishnan S; Elbanna M; Wang J; Hu Q; Glenn ST; Murakami M; Liu L; Gomez EC; Sun Y; Conroy J; Miles KM; Malathi K; Ramaiah S; Anbarasu A; Woloszynska-Read A; Johnson CS; Conroy J; Liu S; Morrison CD; Pili R
    Oncotarget; 2016 Nov; 7(47):76374-76389. PubMed ID: 27823983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.
    Navone NM; van Weerden WM; Vessella RL; Williams ED; Wang Y; Isaacs JT; Nguyen HM; Culig Z; van der Pluijm G; Rentsch CA; Marques RB; de Ridder CMA; Bubendorf L; Thalmann GN; Brennen WN; Santer FR; Moser PL; Shepherd P; Efstathiou E; Xue H; Lin D; Buijs J; Bosse T; Collins A; Maitland N; Buzza M; Kouspou M; Achtman A; Taylor RA; Risbridger G; Corey E
    Prostate; 2018 Dec; 78(16):1262-1282. PubMed ID: 30073676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical optimization of a broad-spectrum anti-bladder cancer tri-drug regimen via the Feedback System Control (FSC) platform.
    Liu Q; Zhang C; Ding X; Deng H; Zhang D; Cui W; Xu H; Wang Y; Xu W; Lv L; Zhang H; He Y; Wu Q; Szyf M; Ho CM; Zhu J
    Sci Rep; 2015 Jun; 5():11464. PubMed ID: 26088171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-Derived Xenografts of Breast Cancer.
    Varešlija D; Cocchiglia S; Byrne C; Young L
    Methods Mol Biol; 2017; 1501():327-336. PubMed ID: 27796962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment and antitumor effects of dasatinib and PKI-587 in BD-138T, a patient-derived muscle invasive bladder cancer preclinical platform with concomitant EGFR amplification and PTEN deletion.
    Chang N; Lee HW; Lim JE; Jeong DE; Song HJ; Kim S; Nam DH; Sung HH; Jeong BC; Seo SI; Jeon SS; Lee HM; Choi HY; Jeon HG
    Oncotarget; 2016 Aug; 7(32):51626-51639. PubMed ID: 27438149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fidelity of a PDX-CR model for bladder cancer.
    Mondal AM; Ma AH; Li G; Krawczyk E; Yuan R; Lu J; Schlegel R; Stamatakis L; Kowalczyk KJ; Philips GK; Pan CX; Liu X
    Biochem Biophys Res Commun; 2019 Sep; 517(1):49-56. PubMed ID: 31303270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-derived xenograft models: an emerging platform for translational cancer research.
    Hidalgo M; Amant F; Biankin AV; Budinská E; Byrne AT; Caldas C; Clarke RB; de Jong S; Jonkers J; Mælandsmo GM; Roman-Roman S; Seoane J; Trusolino L; Villanueva A
    Cancer Discov; 2014 Sep; 4(9):998-1013. PubMed ID: 25185190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Head and neck cancer patient-derived xenograft models - A systematic review.
    Schuch LF; Silveira FM; Wagner VP; Borgato GB; Rocha GZ; Castilho RM; Vargas PA; Martins MD
    Crit Rev Oncol Hematol; 2020 Nov; 155():103087. PubMed ID: 32992152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-derived xenografts: a valuable platform for clinical and preclinical research in pancreatic cancer.
    Wang Y; Cui J; Wang L
    Chin Clin Oncol; 2019 Apr; 8(2):17. PubMed ID: 30943729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applications of the xenograft as a model of invasive transitional cell carcinoma of the bladder.
    Russell PJ; Raghavan D; Philips J; Gregory P
    Prog Clin Biol Res; 1988; 260():167-81. PubMed ID: 3362878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity.
    Mangsbo SM; Broos S; Fletcher E; Veitonmäki N; Furebring C; Dahlén E; Norlén P; Lindstedt M; Tötterman TH; Ellmark P
    Clin Cancer Res; 2015 Mar; 21(5):1115-26. PubMed ID: 25316820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-Derived Xenograft Models in Breast Cancer Research.
    Na D; Moon HG
    Adv Exp Med Biol; 2021; 1187():283-301. PubMed ID: 33983584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-derived sialyl-Tn-positive invasive bladder cancer xenografts in nude mice: an exploratory model study.
    Bernardo C; Costa C; Amaro T; Gonçalves M; Lopes P; Freitas R; Gärtner F; Amado F; Ferreira JA; Santos L
    Anticancer Res; 2014 Feb; 34(2):735-44. PubMed ID: 24511007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capturing colorectal cancer inter-tumor heterogeneity in patient-derived xenograft (PDX) models.
    Prasetyanti PR; van Hooff SR; van Herwaarden T; de Vries N; Kalloe K; Rodermond H; van Leersum R; de Jong JH; Franitza M; Nürnberg P; Todaro M; Stassi G; Medema JP
    Int J Cancer; 2019 Jan; 144(2):366-371. PubMed ID: 30151914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-derived xenografts from non-small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapy.
    Lee HW; Lee JI; Lee SJ; Cho HJ; Song HJ; Jeong DE; Seo YJ; Shin S; Joung JG; Kwon YJ; Choi YL; Park WY; Lee HM; Seol HJ; Shim YM; Joo KM; Nam DH
    Clin Cancer Res; 2015 Mar; 21(5):1172-82. PubMed ID: 25549722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-derived xenografts as tools in pharmaceutical development.
    Izumchenko E; Meir J; Bedi A; Wysocki PT; Hoque MO; Sidransky D
    Clin Pharmacol Ther; 2016 Jun; 99(6):612-21. PubMed ID: 26874468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and characteristics of preclinical experimental models for the research of rare neuroendocrine bladder cancer.
    Hofner T; Macher-Goeppinger S; Klein C; Rigo-Watermeier T; Eisen C; Pahernik S; Hohenfellner M; Trumpp A; Sprick MR
    J Urol; 2013 Dec; 190(6):2263-70. PubMed ID: 23820058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.